Asset profile
MK-2060
Monoclonal antibody
Evidence outlook · lead readout
NCT05027074 · End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT05027074: This was a well-designed, randomized, quadruple-blind, placebo-controlled trial with an adequate sample size (506 participants) and a hard clinical primary endpoint of arteriovenous graft thrombosis. However, the primary endpoint comparison was not statistically significant for either dose tested, so despite the rigorous design, the evidence is inconclusive for a beneficial effect and is graded as moderate.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 57 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| MK-2060: this drug | Phase 2 | Monoclonal antibody | Coagulation Factor XI / activated Factor XIa | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Etelcalcetide (Parsabiv) | Approved | Peptide | Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cells | ||
| Extended-Release Calcifediol (Rayaldee) | Approved | Small molecule | Vitamin D receptor (VDR), via conversion to calcitriol | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Derisomaltose (Monoferric / Monofer) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Pyrophosphate Citrate (Triferic) | Approved | Small molecule | Iron-replacement therapy delivered via dialysate | ||
| Ferumoxytol (Feraheme) | Approved | Nanoparticle | IV iron replacement therapy |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.